IBDEI1DR ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24753,2)
 ;;=^35649
 ;;^UTILITY(U,$J,358.3,24754,0)
 ;;=053.9^^163^1595^24
 ;;^UTILITY(U,$J,358.3,24754,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24754,1,2,0)
 ;;=2^053.9
 ;;^UTILITY(U,$J,358.3,24754,1,5,0)
 ;;=5^HERPES ZOSTER NOS
 ;;^UTILITY(U,$J,358.3,24754,2)
 ;;=^56946
 ;;^UTILITY(U,$J,358.3,24755,0)
 ;;=V66.7^^163^1595^26
 ;;^UTILITY(U,$J,358.3,24755,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24755,1,2,0)
 ;;=2^V66.7
 ;;^UTILITY(U,$J,358.3,24755,1,5,0)
 ;;=5^HOSPICE CARE
 ;;^UTILITY(U,$J,358.3,24755,2)
 ;;=^89209
 ;;^UTILITY(U,$J,358.3,24756,0)
 ;;=V08.^^163^1595^25
 ;;^UTILITY(U,$J,358.3,24756,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24756,1,2,0)
 ;;=2^V08.
 ;;^UTILITY(U,$J,358.3,24756,1,5,0)
 ;;=5^HIV,ASYMPTOMATIC
 ;;^UTILITY(U,$J,358.3,24756,2)
 ;;=^303392
 ;;^UTILITY(U,$J,358.3,24757,0)
 ;;=603.9^^163^1595^27
 ;;^UTILITY(U,$J,358.3,24757,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24757,1,2,0)
 ;;=2^603.9
 ;;^UTILITY(U,$J,358.3,24757,1,5,0)
 ;;=5^HYDROCELE NOS
 ;;^UTILITY(U,$J,358.3,24757,2)
 ;;=^59548
 ;;^UTILITY(U,$J,358.3,24758,0)
 ;;=272.0^^163^1595^28
 ;;^UTILITY(U,$J,358.3,24758,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24758,1,2,0)
 ;;=2^272.0
 ;;^UTILITY(U,$J,358.3,24758,1,5,0)
 ;;=5^HYPERCHOLESTEROLEM
 ;;^UTILITY(U,$J,358.3,24758,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,24759,0)
 ;;=272.4^^163^1595^29
 ;;^UTILITY(U,$J,358.3,24759,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24759,1,2,0)
 ;;=2^272.4
 ;;^UTILITY(U,$J,358.3,24759,1,5,0)
 ;;=5^HYPERLIPIDEMIA NEC/NOS
 ;;^UTILITY(U,$J,358.3,24759,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,24760,0)
 ;;=276.7^^163^1595^30
 ;;^UTILITY(U,$J,358.3,24760,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24760,1,2,0)
 ;;=2^276.7
 ;;^UTILITY(U,$J,358.3,24760,1,5,0)
 ;;=5^HYPERPOTASSEMIA
 ;;^UTILITY(U,$J,358.3,24760,2)
 ;;=^60042
 ;;^UTILITY(U,$J,358.3,24761,0)
 ;;=401.9^^163^1595^31
 ;;^UTILITY(U,$J,358.3,24761,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24761,1,2,0)
 ;;=2^401.9
 ;;^UTILITY(U,$J,358.3,24761,1,5,0)
 ;;=5^HYPERTENSION NOS
 ;;^UTILITY(U,$J,358.3,24761,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,24762,0)
 ;;=401.1^^163^1595^32
 ;;^UTILITY(U,$J,358.3,24762,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24762,1,2,0)
 ;;=2^401.1
 ;;^UTILITY(U,$J,358.3,24762,1,5,0)
 ;;=5^HYPERTENSION,BENIGN
 ;;^UTILITY(U,$J,358.3,24762,2)
 ;;=^269591
 ;;^UTILITY(U,$J,358.3,24763,0)
 ;;=401.0^^163^1595^33
 ;;^UTILITY(U,$J,358.3,24763,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24763,1,2,0)
 ;;=2^401.0
 ;;^UTILITY(U,$J,358.3,24763,1,5,0)
 ;;=5^HYPERTENSION,MALIGNANT
 ;;^UTILITY(U,$J,358.3,24763,2)
 ;;=^73505
 ;;^UTILITY(U,$J,358.3,24764,0)
 ;;=242.90^^163^1595^34
 ;;^UTILITY(U,$J,358.3,24764,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24764,1,2,0)
 ;;=2^242.90
 ;;^UTILITY(U,$J,358.3,24764,1,5,0)
 ;;=5^HYPERTHYROIDISM
 ;;^UTILITY(U,$J,358.3,24764,2)
 ;;=^267811
 ;;^UTILITY(U,$J,358.3,24765,0)
 ;;=272.1^^163^1595^35
 ;;^UTILITY(U,$J,358.3,24765,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24765,1,2,0)
 ;;=2^272.1
 ;;^UTILITY(U,$J,358.3,24765,1,5,0)
 ;;=5^HYPERTRIGLYCERIDEMIA
 ;;^UTILITY(U,$J,358.3,24765,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,24766,0)
 ;;=251.2^^163^1595^36
 ;;^UTILITY(U,$J,358.3,24766,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24766,1,2,0)
 ;;=2^251.2
 ;;^UTILITY(U,$J,358.3,24766,1,5,0)
 ;;=5^HYPOGLYCEMIA NOS
 ;;^UTILITY(U,$J,358.3,24766,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,24767,0)
 ;;=276.1^^163^1595^37
 ;;^UTILITY(U,$J,358.3,24767,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24767,1,2,0)
 ;;=2^276.1
 ;;^UTILITY(U,$J,358.3,24767,1,5,0)
 ;;=5^HYPONATREMIA
